publication . Other literature type . Article . 2016

A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

Jean Sanderson; Andrew Rawdin; Sarah Davis; Susi Sadler; John Stevens; Ruth Wong; Mark Stevenson; Mark Strong; Marrissa Martyn-St James; Peter Selby; ...
Open Access English
  • Published: 01 Oct 2016
  • Publisher: NIHR Journals Library
  • Country: United Kingdom
Abstract
<jats:sec id="abs1-1"><jats:title>Background</jats:title><jats:p>Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture.</jats:p></jats:sec><jats:sec id="abs1-2"><jats:title>Objectives</jats:title><jats:p>To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax<jats:sup>®</jats:sup>and Fosamax<jats:sup>®</jats:sup>Once Weekly, Merck Sharp &amp; Dohme Ltd), risedronic acid (Actonel<jats:sup>®</jats:sup>and Actonel Once a Week<jats:sup>®</jats:sup>, Warner Chilcott UK Ltd), ibandronic acid (Bonviva<jats:sup>®</jats:sup>, Roche Products Ltd) and zoledronic acid (Aclasta...
Subjects
free text keywords: Research Article, Health Policy, Medical technology, R855-855.5, Internal medicine, medicine.medical_specialty, medicine, Zoledronic acid, medicine.drug, Population, education.field_of_study, education, Surgery, Cochrane Library, Clinical trial, FRAX, Ibandronic acid, Cost effectiveness, business.industry, business, Risedronic acid
Any information missing or wrong?Report an Issue